R&D channel feed – Endpoints News

R&D channel feed

Genentech inks $650M deal with protein degradation pioneer Arvinas

8 years ago

Fatal sepsis attacks blight Acorda’s PhIII, triggering new safety measures and torpedoing shares

8 years ago

Sangamo claims a major milestone in gene editing, treating first patient with its zinc finger nuclease tech

8 years ago

Award-winning sepsis project gets $13M and a shot at reopening an R&D avenue as FDA pitches out old gold standard

8 years ago

Pfizer CEO Read hands off drug development responsibilities to his hand picked successor

8 years ago

Prepping a case for canakinumab, Novartis tries to stake out a high-value segment of huge cardio market

8 years ago

Novartis spotlights its top 4 blockbuster late-stage pipeline projects

8 years ago

Novartis co-opts Homology's gene-editing tech for R&D pipeline

8 years ago

Bill Gates has a $100M and a 5-point strategy to end 15 years of failure in Alzheimer’s R&D

8 years ago

Nektar takes the spotlight at SITC touting some promising early data for hard-to-treat cancers

8 years ago

Juno uses lethal neurotox lessons to guide Goldilocks formula for its next-gen CAR-T

8 years ago

An explosion of PD-1/L1 checkpoint studies is crowding the industry pipeline — and that’s a problem

8 years ago

Novartis makes its case on why RTH258 can grab a blockbuster piece of Regeneron's AMD market

8 years ago

Bristol-Myers offers a positive snapshot on early data for an IDO1 rival to Incyte

8 years ago

On the heels of a setback, Sage reports PhIII success in postpartum depression -- but questions linger

8 years ago

Surprise: Did Otonomy bring its lead ear drug back from the dead?

8 years ago

Amgen bets on stem cell company Fortuna Fix in $25M round

8 years ago

OncoSec shares turn hot as microcap reports promising PhII data for an I/O one-two punch

8 years ago

Who are the top 10 players that dominate the cancer drug market? And who's growing fastest?

8 years ago

An early SITC loser: Five Prime shares crushed as analysts fret over a snapshot on lead drug data

8 years ago

FDA gives Cellectis a green light to relaunch off-the-shelf CAR-T studies — with several strings attached

8 years ago

Watch out Sanofi: Takeda's new data on dengue vaccine is good news for PhIII trial

8 years ago

Amgen is shaking up R&D (again), chopping 200 as Genentech targets 130 layoffs

8 years ago

Shooting for a new standard on osteoarthritis, Merck KGaA outlines promising data for a potential game-changer

8 years ago

First page Previous page 286 287 288289290 291 292 Next page Last page